These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 28933272)

  • 1. Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.
    Manyevitch R; Protas M; Scarpiello S; Deliso M; Bass B; Nanajian A; Chang M; Thompson SM; Khoury N; Gonnella R; Trotz M; Moore DB; Harms E; Perry G; Clunes L; Ortiz A; Friedrich JO; Murray IVJ
    Curr Alzheimer Res; 2018; 15(2):164-181. PubMed ID: 28933272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease.
    Jiménez-Jiménez FJ; Molina JA; Gómez P; Vargas C; de Bustos F; Benito-León J; Tallón-Barranco A; Ortí-Pareja M; Gasalla T; Arenas J
    J Neural Transm (Vienna); 1998; 105(2-3):269-77. PubMed ID: 9660105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
    Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
    Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid.
    Lleó A; Núñez-Llaves R; Alcolea D; Chiva C; Balateu-Paños D; Colom-Cadena M; Gomez-Giro G; Muñoz L; Querol-Vilaseca M; Pegueroles J; Rami L; Lladó A; Molinuevo JL; Tainta M; Clarimón J; Spires-Jones T; Blesa R; Fortea J; Martínez-Lage P; Sánchez-Valle R; Sabidó E; Bayés À; Belbin O
    Mol Cell Proteomics; 2019 Mar; 18(3):546-560. PubMed ID: 30606734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Takwoingi Y; Flicker L; Mason SE; McShane R
    Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD008782. PubMed ID: 24913723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF neurotransmitter markers in Alzheimer's disease.
    Beal MF; Growdon JH
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):259-70. PubMed ID: 2879317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synaptic Proteins as Fluid Biomarkers in Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Roveta F; Cermelli A; Boschi S; Ferrandes F; Grassini A; Marcinnò A; Spina M; Rubino E; Borsello T; Vercelli A; Rainero I
    J Alzheimers Dis; 2022; 90(4):1381-1393. PubMed ID: 36278349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
    Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
    Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GABAergic system in Alzheimer's disease: a systematic review with meta-analysis.
    Carello-Collar G; Bellaver B; Ferreira PCL; Ferrari-Souza JP; Ramos VG; Therriault J; Tissot C; De Bastiani MA; Soares C; Pascoal TA; Rosa-Neto P; Souza DO; Zimmer ER
    Mol Psychiatry; 2023 Dec; 28(12):5025-5036. PubMed ID: 37419974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood and CSF chemokines in Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.
    Zhou F; Sun Y; Xie X; Zhao Y
    Alzheimers Res Ther; 2023 Jun; 15(1):107. PubMed ID: 37291639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum.
    Paciotti S; Wojdała AL; Bellomo G; Toja A; Chipi E; Piersma SR; Pham TV; Gaetani L; Jimenez CR; Parnetti L; Chiasserini D
    Alzheimers Res Ther; 2023 Jul; 15(1):124. PubMed ID: 37454217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease.
    Chatterjee M; Del Campo M; Morrema THJ; de Waal M; van der Flier WM; Hoozemans JJM; Teunissen CE
    Alzheimers Res Ther; 2018 Jun; 10(1):52. PubMed ID: 29859129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Vascular Endothelial Growth Factor Levels with Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis.
    Zakariaee SS; Naderi N; Azizi E
    J Prev Alzheimers Dis; 2024; 11(3):721-729. PubMed ID: 38706288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid markers of Alzheimer's disease.
    van Gool WA; Bolhuis PA
    J Am Geriatr Soc; 1991 Oct; 39(10):1025-39. PubMed ID: 1918775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cerebrospinal Fluid Synaptosomal-Associated Protein 25 Levels in Patients with Alzheimer's Disease: A Meta-Analysis.
    Liu Q; Liu H; Zhang S; Yang Q; Shen L; Jiao B
    J Alzheimers Dis; 2022; 89(1):121-132. PubMed ID: 35848017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing.
    Blennow K; Vanmechelen E
    J Neural Transm Suppl; 1998; 53():223-35. PubMed ID: 9700660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.